Drug intelligence / Profile preview

ALC-F010

Development stage: Preclinical
Lead developer: Korea Arlico Pharm
Modality: Small Molecules

Overview

ALC-F010 is a developmental-stage drug candidate being developed by Korea Arlico Pharm for the treatment of endocrine system disorders, specifically diabetes. It is classified as a "new drug" (신약) within the company's research and development pipeline. While the specific molecular target and mechanism of action have not been publicly disclosed, the project represents Korea Arlico Pharm's strategic expansion into the metabolic and endocrine therapeutic areas. As of current reporting, the drug is in the early stages of development.

Beyond the preview

Go deeper on ALC-F010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALC-F010.

Explore the full profile